|

Daratumumab and Recombinant Human Hyaluronidase Clinical Trials

1 actively recruiting trial across 1 location

Also known as: Daratumumab and hyaluronidase

Pipeline

Phase 1: 1

Top Sponsors

  • Roswell Park Cancer Institute1

Indications

  • Recurrent Multiple Myeloma1
  • Refractory Multiple Myeloma1
  • Cancer1

Buffalo, New York1 trial

SX-682 in Combination With Carfilzomib, Daratumumab-Hyaluronidase, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma

Roswell Park Comprehensive Cancer Center

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.